Point estimation for adaptive trial designs I: A methodological review
DS Robertson, B Choodari‐Oskooei… - Statistics in …, 2023 - Wiley Online Library
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic
tendency for the estimate of treatment effect to deviate from its true value,” and states that it is …
tendency for the estimate of treatment effect to deviate from its true value,” and states that it is …
[PDF][PDF] Point estimation for adaptive trial designs
DS Robertson, B Choodari-Oskooei, M Dimairo… - arXiv, 2021 - core.ac.uk
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic
tendency for the estimate of treatment effect to deviate from its true value”, and states that it is …
tendency for the estimate of treatment effect to deviate from its true value”, and states that it is …
Accounting for selection and correlation in the analysis of two-stage genome-wide association studies
DS Robertson, AT Prevost, J Bowden - Biostatistics, 2016 - academic.oup.com
The problem of selection bias has long been recognized in the analysis of two-stage trials,
where promising candidates are selected in stage 1 for confirmatory analysis in stage 2. To …
where promising candidates are selected in stage 1 for confirmatory analysis in stage 2. To …
Point estimation for adaptive trial designs I: a methodological review
DS Robertson, B Choodari-Oskooei, M Dimairo… - arXiv preprint arXiv …, 2021 - arxiv.org
Recent FDA guidance on adaptive clinical trial designs defines bias as" a systematic
tendency for the estimate of treatment effect to deviate from its true value", and states that it is …
tendency for the estimate of treatment effect to deviate from its true value", and states that it is …